Biomed Central Ltd

SHERPA: Unknown

People

  1. Vickers
    Vickers
  2. Postow
    Postow
  3. D'Angelo
    D'Angelo
  4. Offit
    Offit
  5. Budhu
    Budhu
  6. Motzer
    Motzer
  7. Shoushtari
    Shoushtari
  8. Cheung
    Cheung
  9. Voss
    Voss
  10. O'Reilly
    O'Reilly

Groups

  1. Department of Medicine (560)
  2. Solid Tumor Oncology Division (456)
  3. GSK Faculty (293)
  4. Sloan Kettering Institute Postdocs (193)
  5. Population Sciences Research Program (157)
  6. Hematologic Malignancies, Division of (155)
  7. Epidemiology and Biostatistics (152)
  8. Melanoma and Immunotherapeutics Service (148)
  9. Survivorship Research (120)
  10. Surgery (119)
Search Within
Formats
  1. Journal Article (745)
  2. Meeting Abstract (257)
  3. Review (40)
  4. Guidelines (20)
  5. Editorial (10)
  6. Research Letter (7)
  7. Correspondence (4)
  8. Conference Paper (1)
  9. Miscellaneous (1)
Groups
  1. Department of Medicine (560)
  2. Solid Tumor Oncology Division (456)
  3. GSK Faculty (293)
  4. Sloan Kettering Institute Postdocs (193)
  5. Population Sciences Research Program (157)
  6. Hematologic Malignancies, Division of (155)

More Groups

People
  1. Jedd Wolchok (83)
  2. Taha Merghoub (55)
  3. Andrew Vickers (44)
  4. Michael Postow (43)
  5. Matthew Hellmann (30)
  6. Sandra D'Angelo (25)

More People

Years
  1. 2025 (33)
  2. 2024 (60)
  3. 2023 (44)
  4. 2022 (122)
  5. 2021 (91)
  6. 2020 (99)

More Years

Publications
  1. Journal for ImmunoTherapy of Cancer (407)
  2. Breast Cancer Research (67)
  3. BMC Cancer (64)
  4. Genome Biology (47)
  5. Journal of Hematology & Oncology (43)
  6. Journal of Translational Medicine (35)

More Publications

Results (1085)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Initial experience administering BMS-986016, a monoclonal antibody that targets lymphocyte activation gene (LAG)-3, alone and in combination with nivolumab to patients with hematologic and solid malignancies
    Meeting Abstract

    Lipson, E.; Gopal, A.; Neelapu, S. S.; Armand, P.; Spurgeon, S.; Leonard, J. P.; Hodi, F. S.; Sanborn, R. E.; Melero, I.; Gajewski, T. F.; more...
    Journal for ImmunoTherapy of Cancer (2016)

    Fulltext@MSK | Save
  • Immune activation by PEGylated human IL-10 (AM0010) and anti-tumor activity in renal cancer alone and in combination with anti-PD-1
    Meeting Abstract

    Naing, A.; Papadopoulos, K. P.; Autio, K. A.; Wong, D. J.; Patel, M.; Falchook, G.; Pant, S.; Ott, P. A.; Whiteside, M.; Patnaik, A.; more...
    Journal for ImmunoTherapy of Cancer (2016)

    Fulltext@MSK | Save
  • Local intratumoral treatment with low-dose CD40 and TLR4 agonists overcomes resistance to PD-1 blockade to control tumors systemically
    Meeting Abstract

    Khalil, D. N.; Campesato, L. F.; Li, Y.; Merghoub, T.; Wolchok, J. D.
    Journal for ImmunoTherapy of Cancer (2016)

    Fulltext@MSK | Save
  • Dose escalation/confirmation results of ENCORE 601, a phase Ib/II, open-label study of entinostat (ENT) in combination with pembrolizumab (PEMBRO) in patients with non-small cell lung cancer (NSCLC)
    Meeting Abstract

    Johnson, M. L.; Adjei, A. A.; Opyrchal, M.; Ramalingam, S.; Janne, P. A.; Dominguez, G.; Gabrilovich, D.; de Leon, L.; Hasapidis, J.; Diede, S. J.; more...
    Journal for ImmunoTherapy of Cancer (2016)

    Fulltext@MSK | Save
  • Phosphatidylserine targeting antibody in combination with checkpoint blockade and tumor radiation therapy promotes anticancer activity in mouse melanoma
    Meeting Abstract

    Budhu, S.; De Henau, O.; Zappasodi, R.; Schlunegger, K.; Freimark, B.; Hutchins, J.; Barker, C. A.; Wolchok, J. D.; Merghoub, T.
    Journal for ImmunoTherapy of Cancer (2016)

    Fulltext@MSK | Save
  • CX-839-004: A phase I/II study of the safety, pharmacokinetics, and pharmacodynamics of the glutaminase inhibitor CB-839 combined with nivolumab in patients with renal cell carcinoma, melanoma, and non-small cell lung cancer
    Meeting Abstract

    Lam, E.; Tannir, N. M.; Meric-Bernstam, F.; Vaishampayan, U.; Orford, K. W.; Molineaux, C.; Gross, M.; MacKinnon, A.; Voss, M.
    Journal for ImmunoTherapy of Cancer (2016)

    Fulltext@MSK | Save
  • A pilot/phase II study evaluating pembrolizumab plus standard-ofcare chemotherapy in metastatic triple-negative breast cancer, with companion comprehensive immunological monitoring
    Meeting Abstract

    Page, D.; Yu, W.; Conlin, A.; Ruzich, J.; Lewis, S.; Acheson, A.; Kemmer, K.; Perlewitz, K.; Moxon, N. M.; Mellinger, S.; more...
    Journal for ImmunoTherapy of Cancer (2016)

    Fulltext@MSK | Save
  • KEYNOTE-013: An open-label, multicohort phase Ib trial of pembrolizumab in patients with advanced hematologic malignancies
    Meeting Abstract

    Kline, J.; Armand, P.; Kuruvilla, J.; Moskowitz, C.; Hamadani, M.; Ribrag, V.; Zinzani, P. L.; Chlosta, S.; Thompson, S.; Balakumaran, A.; more...
    Journal for ImmunoTherapy of Cancer (2016)

    Fulltext@MSK | Save
  • KEYNOTE-057: Phase II study of pembrolizumab in patients with Bacillus Calmette Guérin (BCG)-unresponsive, high-risk non-muscle-invasive bladder cancer (NMIBC)
    Meeting Abstract

    Kamat, A. M.; Bellmunt, J.; Choueiri, T. K.; Nam, K.; De Santis, M.; Dreicer, R.; Hahn, N. M.; Perini, R.; Siefker-Radtke, A.; Sonpavde, G.; more...
    Journal for ImmunoTherapy of Cancer (2016)

    Fulltext@MSK | Save
  • Avelumab in combination with axitinib versus sunitinib as first-line treatment for patients with advanced renal cell carcinoma: The phase III JAVELIN Renal 101 trial
    Meeting Abstract

    Rini, B. I.; Choueiri, T. K.; Mariani, M.; Albiges, L.; Haanen, J. B.; Atkins, M. B.; Larkin, J.; Schmidinger, M.; Magazzù, D.; di Pietro, A.; more...
    Journal for ImmunoTherapy of Cancer (2016)

    Fulltext@MSK | Save